Evaluating LDL-C control in Indian acute coronary syndrome (ACS) patients- A retrospective real-world study LDL-C control in ACS

Jain, Madhur; Sawant, Rahul; Panchal, Hitanshu; S, Anand; Jena, Anupam; Gupta, Rahul; Kumar, Karthik; Jambunathan, Rajagopal; Modi, Sunil; Mullasari, Ajit; Sinha, Nakul; Shetty, Kimi; Kawatra, Pallavi

doi:10.1016/j.ijcrp.2023.200210

Cited by 1 publication

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study performed in India, it was reported that out of 575 patients included in the study, only 20.9% managed to achieve a target LDL-C of <55 mg/dL (1.4 mmol/L) after one year, despite being on high-intensity statin therapy [19].…”

Section: Real-world Datamentioning

confidence: 99%

Lipid-Lowering Therapy after Acute Coronary Syndrome

Pogran,

Burger,

Zweiker

et al. 2024

JCM

View full text Add to dashboard Cite

Achieving guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets remains a significant challenge in clinical practice. This review assesses the barriers to reaching LDL-C goals and explores the potential solutions to these issues. When aiming for the recommended LDL-C goal, strategies like “lower is better” and “strike early and strong” should be used. The evidence supports the safety and efficacy of intensive lipid-lowering therapy post-acute coronary syndrome (ACS), leading to improved long-term cardiovascular health and atherosclerotic plaque stabilization. Despite the availability of effective lipid-lowering therapies, such as high-intensity statins, ezetimibe, the combination of both, bempedoic acid, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a substantial proportion of patients do not meet their LDL-C targets. Contributing factors include systemic healthcare barriers, healthcare provider inertia, patient non-adherence, and statin intolerance. Statin intolerance, often rather statin reluctance, is a notable obstacle due to perceived or expected side effects, which can lead to discontinuation of therapy. In conclusion, while there are obstacles to achieving optimal LDL-C levels post-ACS, these can be overcome with a combination of patient-centric approaches, clinical vigilance, and the judicious use of available therapies. The safety and necessity of reaching lower LDL-C goals to improve outcomes in patients post-ACS are well-supported by current evidence.

show abstract

Section: Real-world Datamentioning

confidence: 99%